SCHEMBL25301093

SCHEMBL25301093

C[C@H]1COc2nc(C(=O)N3CCOCC3)c(Cc3ccc(F)cc3)cc2N1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ NPC1 O15118 3/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ RAB9A P51151 3/20 0.37
▸ GAA P10253 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ NTRK1 P04629 1/20 0.36
▸ PIK3CD O00329 3/20 0.36
▸ PIK3R2 O00459 3/20 0.36
▸ PIK3CA P42336 3/20 0.36
▸ PIK3CB P42338 3/20 0.36
▸ PIK3CG P48736 3/20 0.36
▸ PIK3R5 Q8WYR1 3/20 0.36
▸ PIK3R3 Q92569 3/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ HPGD P15428 2/20 0.36
▸ CNR2 P34972 1/20 0.35
▸ GRM2 Q14416 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25301094 1.00 KMT2A (0.39) KMT2AMEN1NPC1ALDH1A1RAB9A
SCHEMBL25301086 0.92 TMEM97 (0.37) KMT2AMEN1NPC1ALDH1A1RAB9A
SCHEMBL25301087 0.92 TMEM97 (0.37) KMT2AMEN1NPC1ALDH1A1RAB9A
SCHEMBL25253586 0.91 HRH4 (0.38) KDM4ENTRK1SMN1; SMN2HPGDCNR2
SCHEMBL25290408 0.91 HRH4 (0.38) KDM4ENTRK1SMN1; SMN2HPGDCNR2
SCHEMBL25295511 0.89 CNR2 (0.40) KMT2AMEN1NTRK1CNR2GRM2
SCHEMBL25295512 0.89 CNR2 (0.40) KMT2AMEN1NTRK1CNR2GRM2
SCHEMBL25298378 0.88 ADORA3 (0.35) CNR2GRM2
SCHEMBL25298379 0.88 ADORA3 (0.35) CNR2GRM2
SCHEMBL25289846 0.88 DPP4 (0.38) ALDH1A1SMN1; SMN2CNR2GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12583866-B2 Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as IAP antagonists BEONE MEDICINES I GMBH (CH) 2026-03-24 — — US disclosed
US-20230219975-A1 PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS BEONE MEDICINES I GMBH (CH) 2023-07-13 — — US disclosed
US-20230219975-A1 PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS BEONE MEDICINES I GMBH (CH) 2023-07-13 — — US disclosed
US-20230219975-A1 PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS BEONE MEDICINES I GMBH (CH) 2023-07-13 — — US disclosed
EP-4161937-A1 PYRIDO[2,3-B] [1,4] OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4] OXAZEPINES AS IAP ANTAGONISTS BeiGene, Ltd. (KY) 2023-04-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12583866-B2 Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as IAP antagonists BIRC2, BIRC3, BIRC5 KMT2A 4506/4885MEN1 3715/4885NPC1 3029/4885
US-20230219975-A1 PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS BIRC2, BIRC3, API5 KMT2A 3931/4885MEN1 4097/4885NPC1 4670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback